NOVARTIS
๐จ๐ญSwitzerland
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 144
- Registration Number
- NCT00171561
- Locations
- ๐จ๐ญ
Novartis Pharmaceuticals, Basel, Switzerland
A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00171028
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals, E. Hanover, New Jersey, United States
A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 109
- Registration Number
- NCT00171353
- Locations
- ๐จ๐ญ
Novartis Pharmaceuticals, Basel, Switzerland
Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-09-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 600
- Registration Number
- NCT00171548
- Locations
- ๐จ๐ญ
Novartis Pharmaceuticals, Basel, Switzerland
Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-08-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 17
- Registration Number
- NCT00170742
- Locations
- ๐จ๐ญ
Novartis, Basel, Switzerland
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 250
- Registration Number
- NCT00171405
- Locations
- ๐ฌ๐ง
Investigative Site, London, United Kingdom
VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 86
- Registration Number
- NCT00171080
- Locations
- ๐จ๐ญ
Novartis Pharmaceuticals, Basel, Switzerland
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 507
- Registration Number
- NCT00170937
- Locations
- ๐บ๐ธ
Novartis Pharmaceuticals, E. Hanover, New Jersey, United States
Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 52
- Registration Number
- NCT00171522
- Locations
- ๐บ๐ธ
Beth Israel Deacon Medical Center, Boston, Massachusetts, United States
๐บ๐ธR/D Clinical Research, Inc., Lake Jackson, Texas, United States
๐บ๐ธHeartland Clinical Research, Inc, Omaha, Nebraska, United States
A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00171613
ยฉ Copyright 2024. All Rights Reserved by MedPath